For symptom management of neuropathic pain, the American Academy of Neurology and American Diabetes Association guidelines recommend: First-line: Duloxetine or pregabalin (with appropriate renal dose adjustments) Alternative options: Gabapentin (with renal dose adjustments) or tricyclic antidepressants (with caution in older adults and cardiac disease) Topical treatments: Capsaicin 8% patch or lidocaine 5% patch for localized symptoms Avoid chronic opioid therapy due to limited evidence and safety concerns Non-pharmacological approaches including physical therapy, proper foot care, and pain psychology techniques provide additional benefit
Kt qu cho thy nhm tip tc dng thuc gim tng cng 25,3% trng lng sau 88 tun, trong khi nhm ngng thuc tng cn tr li mt phn, vi mc gim tng cng ch cn 9,9%
9,10 Ongoing use of GLP-1 RAs may be limited by issues related to tolerability, efficacy, access, and cost
Yes, some GLP-1 receptor agonists, such as liraglutide and semaglutide, have been shown to reduce the risk of major cardiovascular events in people with type 2 diabetes and cardiovascular disease
